Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 11/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210795 | 0.90 | TACR1 (0.44) | TACR1 | |
| SCHEMBL8218601 | 0.90 | CARM1 (0.43) | SIGMAR1NR3C1CARM1PRMT6MEN1 | |
| Hydrochloric Acid SCHEMBL4382736 | 0.89 | KCNH2 (0.44) | TACR1 | |
| Hydrochloric Acid SCHEMBL4382723 | 0.89 | CARM1 (0.43) | SIGMAR1NR3C1CARM1PRMT6MEN1 | |
| SCHEMBL8218922 | 0.86 | HTR7 (0.52) | DRD2SIGMAR1KMT2A | |
| SCHEMBL8221599 | 0.86 | KMT2A (0.45) | TACR1CARM1PRMT6MEN1KMT2A | |
| SCHEMBL8212151 | 0.86 | KMT2A (0.45) | CARM1PRMT6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4384778 | 0.85 | HTR7 (0.51) | DRD2SIGMAR1KMT2A | |
| SCHEMBL8218596 | 0.85 | KMT2A (0.48) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4376998 | 0.85 | KMT2A (0.45) | TACR1CARM1PRMT6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CHRM4 142/4885CCR2 1272/4885DRD2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.